Key result
Exposure to anthracycline doses ≥/m2 increased the odds of cardiomyopathy in adult survivors of childhood cancer compared to no exposure.
Cross-Sectional (n=1,853)
No
Adult survivors of childhood cancer exposed to cardiotoxic therapy have a high prevalence of asymptomatic, subclinical cardiac disease, highlighting the need for routine cardiovascular screening.
Answers are grounded in this paper and cite their sources.
Anthracycline doses ≥250 mg/m² associated with cardiomyopathy; hypothesis-generating for screening thresholds, needs prospective validation in survivors.
BACKGROUND: Studies of cardiac disease among adult survivors of childhood cancer have generally relied on self-reported or registry-based data. OBJECTIVE: To systematically assess cardiac outcomes among survivors of childhood cancer. DESIGN: Cross-sectional study. SETTING: St. Jude Children's Research Hospital. PATIENTS: 1853 adult survivors of childhood cancer, aged 18 years or older, who received cancer-related cardiotoxic therapy at least 10 years earlier. MEASUREMENTS: Baseline history and physical examination, fasting metabolic and lipid panels, echocardiography, electrocardiography, and 6-minute walk test. RESULTS: One half of the survivors (52.3%) were men with a median age of 8 years (range, 0 to 24 years) at cancer diagnosis and 31 years (range, 18 to 60 years) at evaluation. Cardiomyopathy was present in 7.4% survivors (newly identified at the time of evaluation in 4.7%), coronary artery disease in 3.8% (newly identified in 2.2%), valvular regurgitation or stenosis in 28.0% (newly identified in 24.8%), and conduction or rhythm abnormalities in 4.4% (newly identified in 1.4%). Nearly all survivors were asymptomatic. The prevalence of cardiac conditions increased with age at evaluation, ranging from 3% to 24% among survivors aged 30 to 39 years to 10% to 37% among those aged 40 years or older. In multivariable analysis, survivors exposed to anthracycline doses of 250 mg/m2 or more had greater odds of cardiomyopathy (odds ratio, 2.7 [95% CI, 1.1 to 6.9]) than those who were not exposed. Survivors exposed to heart radiation also had increased odds of cardiomyopathy (odds ratio, 1.9 [CI, 1.1 to 3.7]) compared with those who were not exposed. Radiation exposure greater than 1500 cGy with any anthracycline exposure conferred the greatest odds for valve findings. LIMITATIONS: Sixty-one percent of survivors exposed to anthracycline chemotherapy or cardiac-directed radiation participated. A comparison group and longitudinal assessments were not available. CONCLUSION: Cardiovascular screening identified considerable subclinical disease among adult survivors of childhood cancer. PRIMARY FUNDING SOURCE: National Cancer Institute, American Lebanese Syrian Associated Charities.
No takes yet. Share an insight, caveat, or question.
Mulrooney et al. (2016) conducted a cross-sectional in Adult survivors of childhood cancer (n=1,853). Anthracycline chemotherapy (≥250 mg/m2) vs. No exposure was evaluated on Cardiomyopathy (OR 2.7, 95% CI 1.1 to 6.9). Exposure to anthracycline doses ≥/m2 increased the odds of cardiomyopathy in adult survivors of childhood cancer compared to no exposure.
Synapse has enriched 10 related papers. Consider them for comparative context: